Oncology Nursing News®

Immuno-Oncology

Risks Versus Benefits in Combining Immunotherapies

Risks Versus Benefits in Combining Immunotherapies

BY RYAN J. SULLIVAN, MD

Immune-Related Adverse Events: What to Know

Immune-Related Adverse Events: What to Know

BY JARUSHKA NAIDOO, MBBCH

Immunotherapy Side Effects: What Nurses Should Look Out For

Immunotherapy Side Effects: What Nurses Should Look Out For

BY BRIELLE BENYON

It's 'Just the Beginning' of Exciting Brain Cancer News

It's 'Just the Beginning' of Exciting Brain Cancer News

BY BRIELLE BENYON

FDA Grants Priority Review to Frontline Pembro to Treat Recurrent, Metastatic HNSCC

FDA Grants Priority Review to Frontline Pembro to Treat Recurrent, Metastatic HNSCC

BY KRISTIE L. KAHL

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

BY JESSICA SKARZYNSKI

Immunotherapy/VEGF Inhibitor Combos May 'Redefine Frontline Setting in mRCC'

Immunotherapy/VEGF Inhibitor Combos May 'Redefine Frontline Setting in mRCC'

BY CAROLINE SEYMOUR

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

BY GINA COLUMBUS

Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer

Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer

Challenges in Oncology Pharmacy

Challenges in Oncology Pharmacy

BY HOWARD COHEN, RPH, MS, FASHP

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.